Melane Sampson, Author at BioTuesdays

Developments

Cercare and Siemens announce global collaboration on CBCT-P guided stroke treatment

Closely held Cercare Medical and Siemens Healthineers (FSE: SHL) have announced a global collaboration to accelerate the adoption of Cone-Beam CT Perfusion (CBCT-P) in acute stroke care, leveraging its capability to...

May 28, 2026

Developments

BioXcel presents positive data for BXCL501 in bipolar or schizophrenia at ASCP

BioXcel Therapeutics (NASDAQ: BTAI) has announced new positive Phase 3 SERENITY At-Home data for BXCL501 in agitation associated with bipolar disorders or schizophrenia, to be presented this week at the 2026 American...

May 28, 2026

Executive Moves

Former FDA official Peter J. Pitts joins BrainStorm BoD

BrainStorm Cell Therapeutics (OTCQB: BCLI) has appointed former FDA associate commissioner, Peter J. Pitts, to its board of directors (BoD), effective immediately. Mr. Pitts is a globally recognized expert in healthcare...

May 28, 2026

Developments

Conexeu launches preclinical program for B.R.E.A.S.T. with WFIRM

Conexeu Sciences (NASDAQ: CNXU) has initiated a preclinical development program for B.R.E.A.S.T. (BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE), its recently unveiled 3D-printed bioregenerative breast matrix...

May 28, 2026

Developments

Kura reports compelling data from trial of FTI in solid tumors

Kura Oncology (NASDAQ: KURA) has reported compelling first-in-human data from the FIT-001 clinical trial of its next-generation farnesyl transferase inhibitor (FTI) darlifarnib in combination with adagrasib in heavily...

May 26, 2026

Developments

Percheron secures pINN from WHO for investigational cancer therapy

Percheron Therapeutics (ASX: PER; OTC: PERCF) has secured a potential international nonproprietary name (pINN) from the World Health Organization (WHO) for its investigational cancer therapy HMBD-002. According to...

May 26, 2026

Feature

Pacylex reshaping cancer treatment with a novel once-daily oral therapy

Closely held Pacylex Pharmaceuticals is developing a first-in-class oral cancer therapy with a novel, broad mechanism of action designed for refractory cancers as both a monotherapy and a future combination therapy.

May 26, 2026

Developments

Assembly broadens program into cholestatic liver diseases

Assembly Biosciences (NASDAQ: ASMB) has announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatitis delta virus (HDV) infection, into primary biliary...

May 22, 2026

Developments

RCH doses first patient in Arch Phase 2 trial of LSALT peptide in CS-AKI

Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) has announced that Royal Columbian Hospital (RCH) has dosed its first patient in the ongoing Phase 2 trial evaluating LSALT peptide as a new drug to prevent acute kidney...

May 22, 2026

Developments

Adagio submits PMA for vCLAS Ventricular Ablation System for VT

Adagio Medical Holdings (NASDAQ: ADGM) has announced the submission of its Premarket Approval (PMA) application to the FDA for the vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent...

May 21, 2026

Author - Melane Sampson

Cercare and Siemens announce global collaboration on CBCT-P guided stroke treatment

BioXcel presents positive data for BXCL501 in bipolar or schizophrenia at ASCP

Former FDA official Peter J. Pitts joins BrainStorm BoD

Conexeu launches preclinical program for B.R.E.A.S.T. with WFIRM

Kura reports compelling data from trial of FTI in solid tumors

Percheron secures pINN from WHO for investigational cancer therapy

Pacylex reshaping cancer treatment with a novel once-daily oral therapy

Assembly broadens program into cholestatic liver diseases

RCH doses first patient in Arch Phase 2 trial of LSALT peptide in CS-AKI

Adagio submits PMA for vCLAS Ventricular Ablation System for VT

Subscribe